Hermine I Brunner, Nicolino Ruperto, Athimalaipet V Ramanan, Gerd Horneff, Kirsten Minden, Inmaculada Calvo Penades, Ekaterina Alexeeva, Gavin Cleary, Sara M Stern, Isabelle Kone-Paut, María Del Rocío Maldonado Velázquez, C Egla Rabinovich, Agustin Remesal, Clovis Artur Silva, Irina Nikishina, Mauro Zucchetto, Laura Brockwell, Oliver Gordon, Sandra Nagel, Fabrizio De Benedetti
OBJECTIVE: To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA, sJIA). METHODS: Patients with pJIA or sJIA from two open-label, 52-week phase 1 b core trials of SC-TCZ who had adequate response per investigator assessment entered the LTE and continued SC-TCZ treatment according to body weight-based dosing regimens until commercial availability or up to 5 years...
March 29, 2024: Rheumatology